AOD-9604: What the Evidence Shows for Fat Loss and Metabolism (2026 Guide)

Executive Summary

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone — specifically amino acids 176 through 191. It was developed by Metabolic Pharmaceuticals in Australia with a specific goal: preserve the fat-burning properties of hGH while eliminating the growth-promoting, glucose-disrupting, and IGF-1-stimulating effects that make full-length hGH inappropriate as a long-term anti-obesity drug. AOD-9604 is the only peptide outside the GLP-1 class to complete Phase IIb human clinical trials specifically for fat loss. That makes the evidence base here more rigorous than most of the peptide space — but also more nuanced, because the commercial development program ended not due to safety failures, but because GLP-1 agonists produced far larger weight-loss effects.

For men optimizing body composition on TRT or peptide protocols, AOD-9604 occupies a specific niche: it adds a targeted lipolytic layer without affecting IGF-1, growth signaling, appetite, or androgen metabolism. This guide covers what the human trial data actually shows, how AOD-9604 compares to semaglutide and tirzepatide, how it fits into TRT protocols, and the dosing and source decisions that matter most. If you are evaluating AOD-9604 as part of a broader fat-loss or body-composition protocol, see our testosterone and weight loss guide, our GLP-1 and TRT combination guide, and our complete peptide therapy beginner's guide for context.

At-a-Glance Comparison

AOD-9604 evidence summary based on published research and clinical trial data as of 2026. Human trial data is from the Metabolic Pharmaceuticals Phase IIb program. Animal data is from independent preclinical research.

What Is AOD-9604 and How Does It Work?

AOD-9604 is often marketed as 'HGH Fragment 176-191' in online peptide communities — the two names describe the same molecule. The pharmaceutical designation (AOD-9604) comes from the Australian development program; the structural name (Fragment 176-191) is used in research and community contexts. Understanding what AOD-9604 is — and more importantly what it is not — is the essential frame before evaluating whether it belongs in your protocol. Buyers searching for aod-9604 peptide usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

AOD-9604 acts through two primary fat metabolism pathways. First, it stimulates beta-3 adrenergic receptors on adipocytes, triggering lipolysis — the breakdown of stored triglycerides into free fatty acids that become available for energy use. This mirrors the fat-mobilizing effect of full-length hGH without activating the growth-promoting GH receptor pathway. Second, animal models show AOD-9604 inhibits lipogenesis — the synthesis of new fat from dietary carbohydrates — producing a dual effect that likely explains why preclinical results were more dramatic than the fat-mobilizing mechanism alone would predict. What AOD-9604 does not do is equally important: it does not stimulate IGF-1 production, does not affect fasting glucose or insulin sensitivity at clinical doses, does not suppress appetite, and has no known interaction with the androgen receptor or testosterone metabolism. This selectivity is what makes it a clean add-on to TRT and peptide protocols — it layers onto existing hormonal optimization without introducing new metabolic or androgenic variables. For a broader view of how fat metabolism intersects with testosterone optimization, see our testosterone and weight loss guide. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The most common misframe is treating AOD-9604 as a GLP-1 alternative for significant weight loss. It is not. The mechanism is fundamentally different — direct lipolysis without appetite suppression or broad metabolic signaling — and the effect size from human trials (~1–2 kg over 12 weeks) is a fraction of what GLP-1 agonists produce. Setting unrealistic expectations leads to abandoning a tool that may be genuinely useful in the right context. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

The Clinical Evidence: What the Phase IIb Trial Actually Showed

AOD-9604 has more human clinical trial data than almost any other body-composition peptide — and that context matters. Most peptides used in body composition protocols (BPC-157, TB-500, ipamorelin, GHK-Cu) have limited to no human RCT data. AOD-9604 went through a full Phase I through Phase IIb development program, including a ~300-subject placebo-controlled efficacy trial. The program ended for commercial reasons, not safety failures. Buyers searching for aod-9604 peptide usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The Phase IIb trial (Metabolic Pharmaceuticals, mid-2000s, published summary data including Ng et al. 2000 in *Endocrinology* for mechanism studies) enrolled approximately 300 obese adults across multiple doses. Key findings: at 1mg/day subcutaneous injection over 12 weeks, subjects lost significantly more body fat than placebo. No significant changes were observed in IGF-1, fasting blood glucose, insulin, or lipid panels. No serious adverse events were attributed to AOD-9604. The effect size was modest — approximately 1–2 kg fat loss advantage over placebo over 12 weeks. The Stier et al. 2013 safety and tolerability study in healthy volunteers confirmed the favorable safety profile across single and repeat dosing. Animal studies, particularly in obese mice (C57BL/6), showed more dramatic results — 50% reduction in body fat accretion at doses proportional to the clinical program. Rodent-to-human translation gaps are common in peptide research; the clinical effect is real but smaller than preclinical models suggested. The commercial program terminated not because the compound failed, but because the bar moved. Semaglutide was producing 8–15% total body weight loss in competing trials. A peptide producing ~1–2 kg advantage could not justify a prescription drug development pathway at that margin. This is critical context for evaluating AOD-9604 today: the mechanism is active and the compound is safe, but the standalone effect size positions it as a precision body-composition tool, not a weight-loss drug. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: No new large-scale human RCTs have been published since the Metabolic Pharmaceuticals program ended. Current evidence is from Phase IIb trial data plus preclinical models and observational clinical data. This limits confidence in exact effect sizes but does not invalidate the mechanism. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

AOD-9604 vs GLP-1 Agonists: When Each Makes Sense

The most common comparison men research is AOD-9604 versus semaglutide or tirzepatide. This comparison matters because the two approaches solve fundamentally different problems through fundamentally different mechanisms — and conflating them leads to wrong protocol decisions in both directions. Buyers searching for aod-9604 peptide usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

GLP-1 agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produce weight loss primarily through appetite suppression and slowed gastric emptying. They activate GLP-1 receptors (and GIP receptors in the case of tirzepatide), reducing hunger signals centrally, decreasing caloric intake, and improving insulin sensitivity. The result is 10–22% total body weight loss in pivotal trials. AOD-9604 produces fat loss through direct beta-3 adrenergic stimulation of adipocytes — no appetite effect, no insulin pathway modulation. The 12-week effect in clinical trials was ~1–2 kg. These are not competing approaches to the same problem; they are different tools for different situations. AOD-9604 makes sense over GLP-1 agonists when: you are already tracking macros and hunger management is not the constraint; you cannot tolerate GLP-1 GI side effects (nausea, constipation, gastroparesis risk); you are adding a targeted fat-loss layer to a TRT or peptide stack without disrupting other protocols; or you want body-composition precision without the lean mass loss risk that GLP-1 agonists carry in the absence of resistance training. GLP-1 makes more sense when: significant total weight loss is the primary objective; metabolic syndrome, prediabetes, or cardiovascular risk is present; or you need appetite regulation as a behavioral support tool. The two approaches are not mutually exclusive — some clinicians use both simultaneously, though no clinical trial data supports the combination. See our tirzepatide vs semaglutide comparison and GLP-1 and TRT guide for more detail on evaluating GLP-1 options. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Using AOD-9604 when significant weight loss is the actual goal — not body-composition precision — leads to disappointment and missed therapeutic opportunity. Be honest about the objective before selecting the tool. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Dosing, Protocols, and What to Track

AOD-9604 dosing is better established than most peptides because of the clinical trial program. The Phase IIb data gives a reliable anchor point: 1mg/day subcutaneous injection produced significant fat loss. Community and clinic practice often uses lower doses with mixed results — understanding the dose-response relationship helps calibrate expectations. Buyers searching for aod-9604 peptide usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Clinical trial dosing: 1mg (1000 mcg)/day SC was the primary efficacious dose in Phase IIb. Lower doses (250 mcg, 500 mcg) were tested in dose-finding studies with less consistent effects. Clinical and community practice protocols typically prescribe 250–500 mcg/day SC in a fasted state, administered in the morning or pre-workout to maximize lipolytic effect. Insulin suppresses lipolysis; administering AOD-9604 with elevated insulin post-meal may blunt the fat-mobilizing effect. The 2+ hours fasted window is the standard recommendation. Cycle length: 12–16 weeks with a rest period. There is no strong evidence for what the optimal rest period should be; most practitioners use 4–8 weeks off. Injection site rotation is important for preventing lipohypertrophy (localized fat changes at repeated injection sites) — rotate between abdomen, thighs, and other standard SC sites. What to track during a cycle: body composition measurements (DEXA is preferred; tape measurements at minimum), fasting glucose and insulin at baseline and week 8, IGF-1 at baseline only (to confirm no off-label GH receptor activation), and weight trends — expect 1–2 lbs of fat loss per month from AOD-9604 alone at community dosing levels. At 1mg/day clinical dosing, effects may be more pronounced. Common stacks: AOD-9604 + CJC-1295/ipamorelin for broader body-composition support; AOD-9604 + BPC-157 or TB-500 for recovery and inflammation management; AOD-9604 + TRT for hormonal optimization with body-composition support. See our ipamorelin vs CJC-1295 guide for details on GH peptide stacking. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Community dosing (250–500 mcg/day) is below the Phase IIb trial dose (1mg/day). Effectiveness at lower doses is less certain. If tracking shows no body composition change after 8–12 weeks at 250 mcg/day, this may reflect a dose-response threshold issue rather than compound failure. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

AOD-9604 and TRT: Integration and Monitoring

Men on TRT often carry residual visceral fat that persists despite optimized testosterone, particularly in the abdominal region. AOD-9604 is one of the cleanest body-composition additions to a TRT protocol precisely because its mechanism is orthogonal to androgenic signaling — it does not interact with the androgen receptor, SHBG, estradiol, or the HPTA axis. Buyers searching for aod-9604 peptide usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

TRT improves muscle protein synthesis, energy, libido, and mood, but it is not a fat-loss drug at physiologic replacement doses. Free testosterone improvements can modestly support fat metabolism through androgen receptor signaling in adipose tissue, but the magnitude is limited. AOD-9604 adds a direct lipolytic layer through a completely separate pathway, without introducing IGF-1 activity, insulin disruption, or hormonal complexity. For men using hCG or enclomiphene alongside TRT to maintain fertility or testicular function, AOD-9604 appears neutral to HPTA activity — an important feature for a protocol that is already managing the LH-FSH-testosterone axis carefully. Protocol integration: most TRT clinics that include AOD-9604 administer it as a separate AM fasted injection on the same schedule (daily or 5 days on, 2 days off). There is no pharmacological reason it cannot be administered on the same day as TRT injections. No TRT-specific monitoring changes are required when adding AOD-9604. Maintain your standard TRT panel (total T, free T, E2, hematocrit, PSA, LH/FSH if using fertility preservation protocols) and add a fasting glucose and insulin baseline given the metabolic context. See our complete TRT guide and TRT monitoring guide for baseline lab framework. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The key monitoring risk is not from AOD-9604 itself but from overinterpreting scale weight changes during a TRT + body-composition protocol. TRT often increases lean mass while AOD-9604 reduces fat mass — the net scale change may appear modest even when body composition is improving significantly. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Safety, Side Effects, and Legal Status in 2026

AOD-9604's safety profile is one of the strongest in the peptide space because of the clinical trial program. Phase I through Phase IIb trials in hundreds of subjects produced no serious adverse events attributed to the compound. The primary risks in real-world use are source quality and incorrect expectations — not pharmacological toxicity. Buyers searching for aod-9604 peptide usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Reported side effects in clinical trials and community use: mild injection site reactions (redness, minor swelling) are the most common complaint, dose-dependent and typically resolving within 24–48 hours with site rotation. Some community users report transient hunger or mild fatigue early in use — the mechanism is unclear and these effects are not consistently reported. No cases of hypoglycemia, serious insulin sensitivity changes, or growth-related adverse events have been reported in the clinical literature. What to monitor: fasting glucose and insulin at baseline and mid-cycle (conservative monitoring, not because of known risk); local injection sites for signs of lipohypertrophy with repeated same-site dosing. Legal status in the United States: AOD-9604 is not a scheduled controlled substance. It is not FDA-approved for any indication. It can be legally compounded and prescribed by licensed physicians through 503A compounding pharmacies. The FDA has not issued specific enforcement guidance against compounded AOD-9604, unlike some other peptides (BPC-157, TB-500) that appeared on FDA compounding risk communications. Source quality is the dominant risk factor. Research chemical suppliers operate entirely outside pharmaceutical manufacturing standards — dosing accuracy, sterility, and contamination risk vary significantly. If using AOD-9604, pharmaceutical-grade compounded product through a licensed clinic is strongly preferred. See our peptide safety and side effects guide and peptide therapy beginner's guide for broader safety framework. To evaluate clinic options, see our clinic comparison tool. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The highest real-world risk is not the compound but the source. Research chemical suppliers are unregulated. Contamination, incorrect concentration, and sterility failures are the primary safety concerns, not AOD-9604 pharmacology. Using pharmaceutical-grade compounded product through a licensed provider eliminates most of this risk. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

AOD-9604 is a targeted fat-loss tool — not a replacement for GLP-1 agonists when significant weight loss is the goal, but a useful low-disruption body-composition layer for men optimizing a TRT or peptide protocol. Source quality and realistic effect-size expectations are the critical variables.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

What is AOD-9604 used for?

AOD-9604 is studied for targeted fat loss via lipolysis stimulation and lipogenesis inhibition. It does not suppress appetite, build muscle, or affect growth hormone levels. Its primary use is as a body-composition add-on to TRT or peptide protocols.

Does AOD-9604 actually work for fat loss?

The human Phase IIb clinical trial showed statistically significant fat loss vs. placebo (~1–2 kg over 12 weeks at 1mg/day). The effect size is modest compared to GLP-1 agonists. Animal models show stronger effects. Real-world outcomes depend on dose, diet, training, and source quality.

How does AOD-9604 differ from semaglutide or tirzepatide?

AOD-9604 targets fat tissue directly via beta-3 adrenergic receptors. GLP-1 agonists like semaglutide suppress appetite and affect multiple metabolic pathways, producing 10–22% total body weight loss. AOD-9604 does not suppress appetite and produces significantly smaller effects. They serve different roles in body-composition protocols.

What is the typical AOD-9604 dose?

Phase IIb clinical trials used 1mg (1000 mcg)/day SC. Community and clinical practice often uses 250–500 mcg/day in a fasted state. Dosing below 250 mcg has limited evidence of efficacy.

Can I use AOD-9604 with TRT?

Yes. AOD-9604 has no known interaction with the androgen receptor, testosterone, SHBG, or estradiol metabolism. It is often used as a body-composition add-on for men on TRT who want to address residual fat mass.

Does AOD-9604 affect IGF-1?

No. Unlike full-length hGH or GH secretagogues, AOD-9604 does not stimulate IGF-1 production. This was specifically confirmed in the Phase IIb human trial and is a core design feature of the molecule.

Is AOD-9604 legal in the United States?

AOD-9604 is not FDA-approved but is not a scheduled controlled substance. It can be legally compounded and prescribed by licensed physicians through 503A compounding pharmacies.

How long does it take to see results with AOD-9604?

The clinical trial showed significant effects over 12 weeks. Most practitioners suggest a minimum 12–16 week cycle for meaningful body composition data. Expect gradual changes — approximately 1–2 lbs of fat loss per month from AOD-9604 alone at community dosing levels.

What peptides stack well with AOD-9604?

AOD-9604 is commonly stacked with CJC-1295 + ipamorelin for broader body composition support, BPC-157 or TB-500 for recovery, and TRT for hormone optimization. No pharmacological conflicts are known with any of these combinations.

Where can I get AOD-9604?

AOD-9604 is available through licensed compounding pharmacies when prescribed by a physician. Reputable online TRT and peptide clinics can evaluate and prescribe it. Research chemical suppliers also sell it, but quality and sterility are not guaranteed outside the pharmaceutical supply chain.